BioWorld

Jan. 20, 2009

View Archived Issues

Peptimmune, Novartis Sign $500M Deal for MS Drug

Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today) Read More

Drop in Manufacturing Demand Prompts Cuts to XOMA's Staff

Read More

Will Health Care Reform Save Biotech, Economy

Read More

NewCo News: Carolus Therapeutics Wants to be King of Cytokine Targeting

Read More

Holiday Notice

Read More

Corrections & Clarifications

Read More

FDA Issues Final Guidance on Rules for GE Animals

Read More

Clinic Roundup

Read More

Other News To Note

Read More